Research performed at UC Santa Barbara points to the drug rapamycin as a potential treatment for kidney disease. The study builds on past research and shows that studies performed on mice are more likely to translate to humans than previously thought. The results are published in the current online issue of the Journal of the American Society of Nephrology. Over 600, 000 people in the U.S., and 12 million worldwide, are affected by the inherited kidney disease known as ADPKD, short for autosomal-dominant polycystic kidney disease. In the U.S., the number of individuals affected by ADPKD is greater than the number affected by cystic fibrosis, muscular dystrophy, hemophilia, Down's syndrome, and sickle cell anemia combined.
Affymax Completes Treatment And Last Patient Follow-up In Phase 3 Program For Investigational Drug, Hematide, To Treat Anemia In Chronic Renal Failure
Affymax, Inc. (Nasdaq:AFFY) announced completion of treatment and follow-up of patients with anemia due to chronic renal failure enrolled in the four-trial, Phase 3 clinical program for the investigational drug Hematide. The company expects to report topline results from all four Phase 3 trials in the second quarter of 2010. The Phase 3 clinical program enrolled approximately 2, 600 chronic renal failure patients at approximately 400 clinical trial sites. "Completion of this comprehensive Hematide program marks a major milestone and we anticipate an intensive period of data compilation and analysis, " said Arlene Morris, president and chief executive officer of Affymax, Inc.
A new study finds that the drug pazopanib (VOTRIENT) slows disease progression by 54 percent in patients with advanced renal cell carcinoma (RCC). This is the first publication of the full data used by the U.S. Food and Drug Administration to approve the drug in October 2009 for the treatment of advanced RCC. "Advanced renal cell carcinoma remains a challenging disease, but treatment has improved with the introduction of new targeted therapies over the past year - including pazopanib, which targets multiple pathways within cancer cells, " said Cora Sternberg, MD, chief of the Department of Medical Oncology at the San Camillo and Forlanini Hospitals in Rome, Italy and the study's lead author.
Researchers have discovered that the combination of three genetic abnormalities significantly impacts how long a prostate cancer patient is likely to survive with the disease, according to the latest edition of the British Journal of Cancer. Scientists at The Institute of Cancer Research (ICR) believe that patients could be tested for these genetic abnormalities to help decide the intensity of treatment they should receive. The team used a technique called fluorescence in situ hybridisation (FISH) to examine three specific genetic alterations in prostate cancer samples from 308 patients: loss of the PTEN gene and rearrangement of the ERG or ETV1 genes.
Evolution Of Open Radical Retropubic Prostatectomy--how Have Open Surgeons Responded To The Challenge Of Minimally Invasive Surgery?
UroToday.com - Over the past seven to eight years there has been a proliferation of minimally invasive surgery (MIS) techniques for the treatment of urologic malignancies. This is no better demonstrated than the radical prostatectomy procedure for patients with prostate cancer. These clinical researchers undertook a unique survey study to assess the influence of MIS on open surgeons with regards to technique, surgical equipment, and perioperative management of patients undergoing surgery for urologic malignancies. This survey was submitted to all members of the Society of Urologic Oncology and assessed the open surgeons' sense of competition from MIS.
The cardiovascular risk that is associated with proteinuria, or high levels of protein in the urine, a common test used by doctors as an indicator of increased risk for progressive kidney disease, heart attack and stroke, has race-dependent effects, according to a new study by researchers at Wake Forest University School of Medicine. The study appears in the January issue of Diabetes Care. "Proteinuria, a long accepted indicator of heart disease risk, has far less impact on blacks than it does on whites, " said Barry Freedman, M.D., John H. Felts III Professor, chief of the Section on Nephrology, and lead researcher on the study. "In the medical community, it is believed that the more protein in a patient's urine, the greater the risk for heart disease and stroke, and this is true - in white populations.